Show simple item record

dc.contributor.authorFitzgerald, Seán
dc.contributor.authorSheehan, Katherine M.
dc.contributor.authorEspina, Virginia
dc.contributor.authorO'Grady, Anthony
dc.contributor.authorCummins, Robert
dc.contributor.authorKenny, Dermot
dc.contributor.authorLiotta, Lance
dc.contributor.authorO'Kennedy, Richard
dc.contributor.authorKay, Elaine W.
dc.contributor.authorKijanka, Gregor S.
dc.date.accessioned2019-12-04T14:06:32Z
dc.date.available2019-12-04T14:06:32Z
dc.date.issued2014-11-13
dc.identifier.citationFitzgerald, Seán, Sheehan, Katherine M, Espina, Virginia, O'Grady, Anthony, Cummins, Robert, Kenny, Dermot, Liotta, Lance, O'Kennedy, Richard, Kay, Elaine W., Kijanka, Gregor S. (2015). High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer. The Journal of Pathology: Clinical Research, 1(1), 54-65. doi: 10.1002/cjp2.5en_IE
dc.identifier.issn2056-4538
dc.identifier.urihttp://hdl.handle.net/10379/15615
dc.description.abstractCeramide synthase 5 is involved in the de novo synthesis of ceramide, a sphingolipid involved in cell death and proliferation. In this study, we investigated the role of ceramide synthase 5 in colorectal cancer by examining ceramide synthase 5 expression, clinico‐pathological parameters and association with survival/death signalling pathways in cancer. Immunohistochemical analysis of CerS5 was performed on 102 colorectal cancer samples using tissue microarrays constructed from formalin‐fixed and paraffin‐embedded tissues. We found strong membranous ceramide synthase 5 staining in 57 of 102 (56%) colorectal cancers. A multivariate Cox regression analysis of ceramide synthase 5 expression adjusted for disease stage, differentiation and lymphovascular invasion revealed reduced 5‐year overall survival (p = 0.001) and 5‐year recurrence‐free survival (p = 0.002), with hazard ratios of 4.712 and 4.322, respectively. The effect of ceramide synthase 5 expression on tumourigenic processes was further characterised by reverse phase protein array analysis. Reverse phase protein arrays were generated from laser capture microdissection‐enriched carcinoma cells from 19 fresh‐frozen colorectal cancer tissues. Measurements of phosphorylation and total levels of signalling proteins involved in apoptosis, autophagy and other cancer‐related pathways revealed two distinct signalling networks; weak membranous ceramide synthase 5 intensity was associated with a proteomic network dominated by signalling proteins linked to apoptosis, whereas strong ceramide synthase 5 intensity was associated with a proteomic sub‐network mostly composed of proteins linked to autophagy. In conclusion, high ceramide synthase 5 expression was found in colorectal cancer tissue and was associated with poorer patient outcomes. Our findings suggest that this may be mediated by a transition from apoptotic to autophagy signalling pathways in ceramide synthase 5 High expressing tumours, thus implicating ceramide synthase 5 in the progression of colorectal cancer.en_IE
dc.description.sponsorshipWe gratefully acknowledge the help of Dr. Joanna Fay, Deirdre Hyland and our surgical colleagues in Beaumont Hospital and Martin Somers from the Biomedical Diagnostics Institute for his help in editing of illustrations. This work was supported by grants from the Irish Cancer Society CRF10KIJ, the Science Foundation Ireland 10/CE/B1821 and Pathological Society Visiting Fellowship VF 2013/04/01.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherWileyen_IE
dc.relation.ispartofThe Journal of Pathology: Clinical Researchen
dc.subjectceramide synthase 5en_IE
dc.subjectcolorectal canceren_IE
dc.subjectprognosisen_IE
dc.subjectapoptosisen_IE
dc.subjectautophagyen_IE
dc.subjectreverse phase protein arraysen_IE
dc.subjectlaser capture microdissectionen_IE
dc.titleHigh CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal canceren_IE
dc.typeArticleen_IE
dc.date.updated2019-11-27T11:34:50Z
dc.identifier.doi10.1002/cjp2.5
dc.local.publishedsourcehttps://doi.org/10.1002/cjp2.5en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderIrish Cancer Societyen_IE
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderPathological Society of Great Britain and Irelanden_IE
dc.internal.rssid17361155
dc.local.contactSeán Fitzgerald, Physiology, School Of Medicine, Nui Galway. Email: sean.fitzgerald@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionSUBMITTED
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Centre for Science Engineering and Technology (CSET)/10/CE/B1821/IE/CSET BDI: Biomedical Diagnostics Institute/en_IE
nui.item.downloads137


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record